Neurogene Inc. (NGNE)

Market Cap	268.13M
Revenue (ttm)	925,000
Net Income (ttm)	-80.87M
Shares Out	14.26M
EPS (ttm)	-4.35
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	149,287
Open	17.82
Previous Close	17.66
Day's Range	17.14 - 18.90
52-Week Range	6.88 - 74.49
Beta	n/a
Analysts	Buy
Price Target	39.83 (+111.86%)
Earnings Date	May 9, 2025

About NGNE

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreements with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The com...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 107
• Stock Exchange: NASDAQ
• Ticker Symbol: NGNE
• Website: https://www.neurogene.com

Analyst Forecast

According to 6 analysts, the average rating for NGNE stock is "Buy." The 12-month stock price forecast is $39.83, which is an increase of 111.86% from the latest price.

Price Target

$39.83

(111.86% upside)

Analyst Consensus: Buy